NASDAQ:IMMP Immutep (IMMP) Stock Price, News & Analysis $1.86 -0.02 (-1.06%) Closing price 04:00 PM EasternExtended Trading$1.91 +0.05 (+2.47%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immutep Stock (NASDAQ:IMMP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immutep alerts:Sign Up Key Stats Today's Range$1.85▼$1.9050-Day Range$1.41▼$2.4952-Week Range$1.32▼$2.86Volume68,861 shsAverage Volume217,630 shsMarket Capitalization$271.63 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewImmutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Read More… Immutep Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreIMMP MarketRank™: Immutep scored higher than 25% of companies evaluated by MarketBeat, and ranked 842nd out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingImmutep has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmutep has received no research coverage in the past 90 days.Read more about Immutep's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immutep are expected to decrease in the coming year, from ($0.40) to ($0.50) per share.Price to Book Value per Share RatioImmutep has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immutep's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.91% of the float of Immutep has been sold short.Short Interest Ratio / Days to CoverImmutep has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.Change versus previous monthShort interest in Immutep has recently increased by 0.99%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmutep does not currently pay a dividend.Dividend GrowthImmutep does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.91% of the float of Immutep has been sold short.Short Interest Ratio / Days to CoverImmutep has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.Change versus previous monthShort interest in Immutep has recently increased by 0.99%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.24 News SentimentImmutep has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Immutep this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for IMMP on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows4 people have added Immutep to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immutep insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.07% of the stock of Immutep is held by insiders.Percentage Held by InstitutionsOnly 2.32% of the stock of Immutep is held by institutions.Read more about Immutep's insider trading history. Receive IMMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMP Stock News HeadlinesImmutep (NASDAQ:IMMP) Stock Rating Lowered by Wall Street ZenMay 30 at 2:11 AM | americanbankingnews.comImmutep’s Efti Combination Therapy Shows Promising Results in Soft Tissue Sarcoma TrialMay 28, 2025 | tipranks.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.June 2, 2025 | Brownstone Research (Ad)Immutep Limited: Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue SarcomaMay 27, 2025 | finanznachrichten.deImmutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue SarcomaMay 27, 2025 | globenewswire.comImmutep’s Efti Combination Therapy Achieves Success in Phase II Soft Tissue Sarcoma TrialMay 25, 2025 | tipranks.comImmutep reports promising lung cancer trial resultsMay 16, 2025 | investing.comImmutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung CancerMay 15, 2025 | finance.yahoo.comSee More Headlines IMMP Stock Analysis - Frequently Asked Questions How have IMMP shares performed this year? Immutep's stock was trading at $2.17 at the beginning of 2025. Since then, IMMP shares have decreased by 14.3% and is now trading at $1.86. View the best growth stocks for 2025 here. Who are Immutep's major shareholders? Immutep's top institutional investors include Meridian Wealth Management LLC (0.26%), XY Capital Ltd (0.09%), Jane Street Group LLC (0.04%) and Simplex Trading LLC. How do I buy shares of Immutep? Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immutep own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immutep investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Pfizer (PFE), Broadcom (AVGO) and GE Aerospace (GE). Company Calendar Today6/02/2025Fiscal Year End6/30/2025Next Earnings (Estimated)7/29/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMMP CIK1506184 Webwww.immutep.com Phone(128) 315-7003Fax61-2-8569-1880Employees2,021Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+276.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio18.25 Quick Ratio18.25 Sales & Book Value Annual Sales$5.14 million Price / Sales52.85 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book1.77Miscellaneous Outstanding Shares146,039,000Free Float141,090,000Market Cap$271.63 million OptionableOptionable Beta1.80 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:IMMP) was last updated on 6/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Gold analyst, Sean Brodrick, gave everyday investors an advance notice of this historic surge. When the bul...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.